

Beckman Coulter unveils DxC 500 AU chemistry analyzer

Feb. 5, 2024—[Beckman Coulter Diagnostics](#) unveiled its DxC 500 AU chemistry analyzer today at Medlab Middle East in Dubai. The analyzer features advanced automation technology, onboard guided workflows, and standardized reagents. Its menu of more than 120 assays has been independently and objectively verified for high-quality Six Sigma performance.

“Hub-and-spoke clinical laboratory models optimize resources to improve access to testing services and enhance overall standardization for quality testing and positive impact on inventory and cost management across a health system. The new DxC 500 AU chemistry analyzer advances capabilities of spoked labs with a broad menu of high-quality assays that deliver consistent, commutable results across Beckman Coulter’s AU clinical chemistry systems, positively impacting clinical decision-making and patient outcomes,” Kathleen Orland, senior vice president and general manager, chemistry and immunoassay business unit, Beckman Coulter Diagnostics, said in a press statement.

The DxC 500 received FDA clearance in July 2023. It is for in vitro diagnostic use only and is available in North America and the Middle East. Worldwide commercial availability is planned for March.